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Aims and objectives: Although clopidogrel combined with aspirin is the most commonly used
dual drug combination to avert thrombotic events in patients with coronary artery disease,
the poor responsiveness to clopidogrel remains a concern. The objective of the current study
is to assess the extent of resistance to clopidogrel, prasugrel, and ticagrelor in a real life set of
patients with coronary artery disease who underwent percutaneous coronary intervention
(PCI).
Materials and methods: A total of 539 patients, who underwent PCI and were on aspirin and on
any of the three drugs, namely, clopidogrel, prasugrel and ticagrelor, were followed up
regularly in the outpatient department. After 24 h of initiation of antiplatelet medication,
response to the treatment in all the patients was assessed using thrombelastography. The
average percentage platelet inhibition was assessed along with the resistance and sensitiv-
ity to the drug in each patient. Sensitivity and resistance to the speciﬁc drug was deﬁned as
>50% and <50% of mean platelet inhibition, respectively.
Results: About 99.15% of the patients treated with ticagrelor were sensitive to the drug and
the difference between ticagrelor, clopidogrel, and prasugrel groups for sensitivity was
signiﬁcant with a p value of 0.00001, in favor of ticagrelor. It was also found that ticagrelor
was signiﬁcantly ( p value of 0.001) associated with least resistance as compared with the
other drugs assessed in the study.
Conclusions: Use of ticagrelor as dual therapy along with aspirin in patients with coronary
artery disease (CAD) and undergoing PCI was associated with a signiﬁcantly higher mean
percentage platelet inhibition, higher sensitivity, and lower resistance as compared with the
usage of clopidogrel or prasugrel.
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1. Introduction
The Million Death Study reported that cardiovascular disease
(CVD) was responsible for 30% mortality in males and 25%
mortality in females in India.1 In 2008, of the >2.5 million
deaths due to CVD in India, two-thirds were due to coronary
heart disease (CHD) indicating the rapidly escalating burden.2
2. Acute coronary syndrome (ACS) and role of
platelets
As the primary critical step in hemostasis, platelets are
activated in the presence of an agonist in response to vessel
injury. The further platelet cascade involving adhesion,
activation, and aggregation is depicted in Fig. 1.3
4
Table 1 – Platelet function tests.4
Test Method
Light transmission
aggregometry
Used to measure low-shear,
platelet-to-platelet aggregation
VerifyNowTM Fully automated
Measures levels of antiplatelet
therapy
Flow cytometry Uses whole-blood samples
Measures platelet glycoproteins
and activation markers
Uses light-emitting ﬂuorescence to
detect platelet activation
Flow cytometry using
VASP assay
Monitors P2Y12 platelet receptor
inhibition
PFA-100® Assesses high-shear platelet
adhesion and aggregation
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The various types of platelet function tests are compared in
Table 1.
2.2. Thromboelastography (TEG)5
The TEG Platelet Mapping assay relies on evaluation of clot
strength to enable a quantitative analysis of platelet function.
TEG analysis provides the measure of maximum platelet
function, and hence the degree of hypercoagulability and
extent of inhibition needed to make the platelet therapy
personalized and helps deduce the:
 Resistance to and effect of antiplatelet therapy.
 Therapeutic level of the therapy.
 Risk for ischemic or bleeding event.
2.3. Currently available antiplatelet agents
2.3.1. Clopidogrel
Clopidogrel is a pro-drug, which binds to P2Y12 receptors
irreversibly, rendering the receptor unable to respond to
adenosine diphosphate (ADP), thus reducing platelet func-
tion.6 Its effect on platelet function lasts for the lifetime of the
affected platelet. It has a slow onset of action and is associated
with high interindividual variability with high plateletFig. 1 – Platelet activation in response to agonist.reactivity despite treatment and resistance during long-term
therapy.
These factors make it difﬁcult to predict the degree of
antiplatelet response to clopidogrel. The Gauging Responsive-
ness with A VerifyNow assay—Impact on Thrombosis and
Safety (GRAVITAS) trial evaluated the effects of increasing the
dose of clopidogrel in patients with inadequate inhibition of
platelet function on standard dose treatment and noted that
some patients continued to have very high platelet reactivity
on higher doses of clopidogrel.7
2.3.2. Prasugrel
Prasugrel is a thienopyridine and a pro-drug that needs to be
converted to an active metabolite. Prasugrel attains inhibition of
platelet aggregation (IPA) within 15–30 min after a loading dose
of 60 mg and attains a maximum IPA of 60–70% within 2–4 h.
The IPA during maintenance treatment is at an average of 50%.7
Prasugrel binds to the P2Y12 receptors irreversibly and
produces inhibition of platelet function for the lifetime of the
affected platelet. Prasugrel effects are much more predictable
as revealed in the Trial to Assess Improvement in Therapeutic
Outcomes by Optimizing Platelet Inhibition with Prasugrel–
Thrombolysis in Myocardial Infarction (TRITON-TIMI) study.7
Although prasugrel resistance has not been reliably
described, some studies have demonstrated prasugrel resis-
tance. Bonello et al. reported a high rate of prasugrel resistance
using the vasodilator-stimulated phosphoprotein index.8
Silvano et al. described a rare case of both clopidogrel and
prasugrel resistance in a patient without diabetes, with acute
STEMI due to stent thrombosis.9 Morel et al. also observed
prasugrel 'resistance' in 19% of cases with CKD.10
2.3.3. Ticagrelor
Ticagrelor is a directly acting cyclopentyltriazolo-pyrimidine
(CPTP) class molecule, which does not require conversion into
an active metabolite. It reversibly inhibits the P2Y12 receptors
on platelets.
Ticagrelor results in an average IPA of 80–90% at 2–4 h after
180 mg loading dose. The IPAs achieved by ticagrelor were
higher than the IPA typically seen with clopidogrel of around
50%.11
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 6 2 4 – 6 3 1626The end result of PLATelet inhibition and patient Outcomes
(PLATO) trial, which was a head-to-head comparison of
ticagrelor and clopidogrel in hospitalized patients with an
ACS, saw a signiﬁcant reduction in the composite of
cardiovascular death, nonfatal MI, and stroke with ticagrelor
without any difference in the overall incidence of fatal or
major bleeding. This was the ﬁrst time that an OAP agent
(ticagrelor) resulted in a signiﬁcant reduction in the overall
death rate. Moreover, the PLATO PlateLET substudy demon-
strated that antiplatelet effect both during initiation of
treatment and maintenance therapy was signiﬁcantly higher
with ticagrelor than with clopidogrel.7
2.3.4. Clopidogrel resistance
Clopidogrel resistance can be deﬁned as the failure of therapy
in patients for whom clopidogrel does not achieve signiﬁcant
platelet inhibition and results in recurrent ischemic events.12
Numerous studies using different platelet function tests
provided estimates of the prevalence ranging from 16.8% to
21% for clopidogrel resistance.13
Variable response to clopidogrel is well documented but a
standardized deﬁnition for individual responsiveness to
clopidogrel is not present. Nonetheless, the common termi-
nologies used are ‘‘low-responder,’’ ‘‘hyporesponder,’’ ‘‘semi-
responder,’’ and ‘‘suboptimal responder’’.13 In general,
patients showing <70% but >30% aggregation are deﬁned as
hyporesponders and <30% aggregation as resistant.14
2.3.4.1. Clopidogrel resistance: global and Indian data. Several
international studies on clopidogrel resistance showed 5–44%
of clopidogrel resistance in patients who underwent PCI
(Table 2). The Indian data also correspond to the international
data with a similar prevalence of clopidogrel resistance
(Table 3).
With this background, we conducted the present study to
determine the extent of resistance to clopidogrel, prasugrel,Table 3 – Observed clopidogrel resistance in Indian
studies.
Study authors Observed clopidogrel resistance
Kar et al.24 13% nonresponders and 19%
semiresponders
Kumar et al.25 3–13%
Guha et al.14 12.5–19.5%
Table 2 – Observed clopidogrel resistance in international
studies.
Study authors Observed clopidogrel resistance
Jaremo et al.15 28%
Gurbel et al.16 31–35%
Müller et al.17 5–11%
Mobley et al.18 30%
Lepantalo et al.19 40%
Angiolillo et al.20 44%
Matetzky et al.21 25%
Dziewierz et al.22 23%
Lev et al.23 24%and ticagrelor in a real life set of patients with coronary artery
disease.
3. Methodology
3.1. Study population and design
This is a prospective, comparative, observational single-center
cohort study, which included 539 consecutive patients who
underwent a PCI at Kokilaben Dhirubhai Ambani Hospital and
Medical Research Institute, Mumbai. The institutional review
board of the hospital approved the study protocol.
Patients were eligible if they were ≥18 years of age and had
conﬁrmed CAD and underwent PCI. The exclusion criteria
were known allergy to clopidogrel, prasugrel, or ticagrelor; a
platelet count less than 100  109/L or greater than 500  109/L;
any active bleeding or history of gastrointestinal bleeding
within the previous 2 months; any other major surgical
procedure within 2 weeks prior to the study; and pregnancy.
All patients who underwent PCI and were considered for the
study were on aspirin and on any of the three drugs, namely,
clopidogrel, prasugrel, and ticagrelor and were followed up
regularly in the outpatient department.
In all patients, response to the treatment was assessed
using thrombelastography or TEG® 24 h after initiation of the
second antiplatelet medication. The percentage platelet
inhibition was assessed along with the resistance and
sensitivity to the drug. Patients resistant to clopidogrel were
shifted to either prasugrel or ticagrelor, while patients
resistant to prasugrel were switched to ticagrelor and then
the percent platelet inhibition was reassessed again after 24–
48 h. The patients who were resistant to ticagrelor were
continued on the same and rechecked after 24 h.
3.2. Blood sampling
Each blood sample required collection of 10 ml of blood into
Vacutainer tubes (BD Medical Systems) containing EDTA,
sodium citrate (3.2%), and heparin (in separate tubes).
3.3. Thrombelastography parameters measured
Thrombelastography or TEG® was used to measure the
percentage of platelet inhibition by aspirin, clopidogrel,
prasugrel, or ticagrelor. The TEG parameters recorded in the
present study include:
1. Reaction time (R), the time required from the start of blood
sample test to ﬁbrin formation; normal range is 2–8 min;
>8 min is enzymatic hypocoagulability, and <2 min is
enzymatic hypercoagulability.
2. Maximum amplitude (MA): the MA of platelet function;
normal is 51–69 mm, <51 mm denotes hypocoagulability;
>69 mm denotes hypercoagulability.
As MA, which represents the maximal clot strength, can be
ascertained by the binding of activated platelets to a ﬁbrin
mesh, 360 ml of heparinized blood was added to 10 ml of
Activator F (Reptilase and Factor XIIIa) in channel 1. Thus, the
contribution of each ﬁbrin meshwork to clot strength (MAFibrin)
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Fig. 2 – Average percent platelet inhibition with three
different drugs studied. The average % platelet inhibition
with ticagrelor was statistically significant within the
group with a p value of 0.001 by applying ANOVA.
Fig. 3 – Response to antiplatelet therapy with clopidogrel,
prasugrel, and ticagrelor. Percentage of patients sensitive
to ticagrelor was statistically significant within the group
with a p value of 0.00001333 by chi-square.
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 6 2 4 – 6 3 1 627was assessed in channel 1. In channels 2 and 3, 360 ml of
heparinized blood was added to 10 ml of ADP (ﬁnal concentra-
tion 2 mM) and 10 ml of arachidonic acid (AA; ﬁnal concentra-
tion 1 mM), respectively along with 10 ml of Activator F.
Channels 2 (MAADP) and 3 (MAAA) help calculate the contribu-
tion of platelets, as activated by ADP or AA, respectively, to clot
strength. Maximal clot strength with maximally stimulated
platelets (MAThrombin) was assessed in channel 4 by adding
360 ml of Kaolin-activated citrated blood to calcium chloride
0.2 M, 20 ml.
Percentage platelet inhibition is deﬁned by the extent of
nonresponse of the platelet ADP or TXA2 receptor to the
exogenous ADP and AA as measured by TEG MA. The
percentage platelet aggregation to agonist can be calculated
by: [(MAADP/AA  MAFibrin)/(MAThrombin  MAFibrin)  100]. This
calculation is performed by the TEG-PM software. Thus, the
percentage platelet inhibition due to clopidogrel, prasugrel,
and ticagrelor was calculated.
3.4. Deﬁnition of outcomes
The percentage of patients sensitive and resistant to and the
average percentage platelet inhibition with the ADP receptor
antagonists, namely clopidogrel, prasugrel, and ticagrelor, were
recorded and were considered as the primary outcome of the
study. The average platelet inhibition was analyzed in both the
resistant and sensitive groups for each of the ADP receptor
antagonists. Sensitivity and resistance to the speciﬁc drug was
deﬁned as >50% and <50% of mean platelet inhibition,
respectively.
The effect of other variables, including age (>60 years and <60
years), creatinine values (<1 mg/dL and >1 mg/dL), weight
(>60 kg and <60 kg), hypertension, and diabetes on the
sensitivity and resistance to oral antiplatelet therapy with ADP
receptor antagonists, were recorded as secondary outcomes.
In addition, the efﬁcacy of prasugrel on clopidogrel
nonresponders and of ticagrelor on clopidogrel and prasugrel
nonresponders was also evaluated as the secondary outcome.
3.5. Statistical analysis
Data were analyzed using R (open source statistical software)
and Excel statistics software package. Categorical variables
were compared using the Chi-square (x2) test while continuous
variables were compared between multiple groups using
independent sample t tests and analysis of variance (ANOVA),
with p < 0.05 considered statistically signiﬁcant.
4. Results
4.1. Study population
A total of 539 patients were enrolled in this study. The mean
age of patients in the study population was 59.12 years and the
mean weight was 73.3 kg. All 539 patients were treated with
aspirin, 241 were tested for clopidogrel, 156 for prasugrel and
235 for ticagrelor.
Additionally those resistant to either clopidogrel or
prasugrel were shifted to another drug and retested.4.2. Effects of clopidogrel, prasugrel, and ticagrelor on
platelet inhibition
The study found that the mean percentage platelet inhibition
was signiﬁcantly higher in patients with ticagrelor as
compared with clopidogrel and with prasugrel ( p value of
0.0001 and 0.0043, respectively). In addition, the average
percent platelet inhibition in patients treated with clopidogrel
was signiﬁcantly lesser as compared with those treated with
prasugrel with a p value of 0.0001, as shown in Fig. 2.
4.3. Response to treatment
As shown in Fig. 3, about 99.15% of the patients treated with
ticagrelor were sensitive to the drug and the difference between
the groups for sensitivity was signiﬁcant ( p value of 0.00001) in
favor of ticagrelor. It was also found that ticagrelor was
signiﬁcantly ( p value of 0.001) associated with the least
resistance as compared with the other drugs in the group.
4.4. Effects of secondary parameters on the response to
treatment
The number of patients sensitive and resistant to oral
antiplatelet therapy with the ADP receptor antagonists
clopidogrel, prasugrel, and ticagrelor in each of the subgroups,
including age (>60 years and <60 years), creatinine values
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Fig. 4 – Mean % platelet inhibition in >60 years of age group.
Clopidogrel vs. prasugrel, p value = 0.0001; clopidogrel vs.
ticagrelor, p value = 0.00001; ticagrelor vs. prasugrel, p
value = 0.0022.
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Fig. 6 – Mean % platelet inhibition in patients with
creatinine values of >1 mg/dL. Clopidogrel vs. prasugrel, p
value = 0 .00001; clopidogrel vs. ticagrelor, p
value = 0.00001; ticagrelor vs. prasugrel, p value = 0.0036.
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tension, and diabetes, are highlighted in Figs. 4–8.
4.5. Impact of age and weight on the response to treatment
Ticagrelor was associated with signiﬁcantly higher mean
percentage platelet inhibition in the group >60 years and in
the group <60 kg of weight as compared with clopidogrel and
prasugrel (Figs. 4 and 5). This suggested that age and weight
were not a factor in the superior response of ticagrelor over
clopidogrel or prasugrel.
4.6. Impact of creatinine level on the response to treatment
In patients with creatinine levels of >1 mg/dL, signiﬁcantly
more patients were sensitive; and signiﬁcantly, fewer patients
were resistant in the ticagrelor group as compared with
clopidogrel with the p value of 0.0005. Ticagrelor was
associated with signiﬁcantly higher mean percentage platelet
inhibition in the group of patients with creatinine values of
>1 mg/dL as compared with clopidogrel and prasugrel (Fig. 6).
4.7. Impact of cardiovascular risk factors on the response
to treatment
4.7.1. Hypertension
About 98.6% of patients were sensitive in the ticagrelor group
as compared with 70.3% to clopidogrel ( p = 0.001) and 93.5% to
prasugrel ( p = 0.01). Ticagrelor was associated with the least59.98
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Fig. 5 – Mean % platelet inhibition in <60 kg of weight group.
Clopidogrel vs. prasugrel, p value = 0.00001; clopidogrel vs.
ticagrelor, p value = 0.00001; ticagrelor vs. prasugrel, p
value = 0.0002.percentage of resistant patients (1.4%) as compared with
prasugrel (6.5%; p = 0.01) and clopidogrel (29.7%; p = 0.001). The
difference between clopidogrel and prasugrel was also
signiﬁcant ( p < 0.00001).
Ticagrelor was associated with signiﬁcantly higher mean
percentage platelet inhibition in patients with hypertension as
compared with clopidogrel and prasugrel (Fig. 7).
4.7.2. Diabetes
In the diabetic subgroup, a total of 98.8% patients were
sensitive in the ticagrelor group as compared with 70.4% in the
clopidogrel ( p = 0.001) and 91.4% in the prasugrel ( p = 0.08)
groups. Ticagrelor was associated with the least percentage of
resistant patients (1.2%) as compared with prasugrel (8.6%;
p = 0.08) and clopidogrel (29.6%; p = 0.001).
Ticagrelor was associated with signiﬁcantly higher mean
percentage platelet inhibition in patients with diabetes as
compared with clopidogrel. While the mean percentage platelet
inhibition with ticagrelor was also higher than that with
prasugrel, this difference was not statistically signiﬁcant (Fig. 8).
4.8. Effect of ticagrelor in patients resistant to clopidogrel
and prasugrel
A total of 9 patients resistant to clopidogrel were shifted to
ticagrelor loading and maintenance dose. All these patients68.17
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Fig. 7 – Mean % platelet inhibition in patients with
hypertension. Clopidogrel vs. prasugrel, p value = 0.00001;
clopidogrel vs. ticagrelor, p value = 0.00001; ticagrelor vs.
prasugrel, p value = 0.0139.
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Fig. 8 – Mean % platelet inhibition in patients with diabetes.
Clopidogrel vs. prasugrel, p value = 0.00001; clopidogrel vs.
ticagrelor, p value = 0.00001; ticagrelor vs. prasugrel, p
value = 0.6642.
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 6 2 4 – 6 3 1 629became sensitive to ticagrelor with the mean percent platelet
inhibition of 90%. The mean percent platelet inhibition
increased from 14.87% to 90% in these patients after switching.
In addition, 2 patients resistant to prasugrel who were
shifted to ticagrelor became sensitive to ticagrelor with the
mean percent platelet inhibition of 90%. Among 52 patients
resistant to clopidogrel and who were switched to prasugrel, 50
patients became sensitive and 2 were resistant to prasugrel
treatment with the mean platelet inhibition rate of 86% and
44%, respectively.
A total of 2 patients who were resistant to ticagrelor
continued with the same treatment and became sensitive after
a further 24 h of continued treatment with ticagrelor.
4.9. Safety
No fatal reaction to any antiplatelet drug was recorded. One
patient on clopidogrel and three patients on prasugrel had
gastrointestinal bleeding that required blood transfusion. No
serious bleeding requiring blood transfusion was recorded
with ticagrelor. Three patients on ticagrelor had to be switched
to prasugrel due to dyspnea. Minor bleeding, such as dental
bleeds or nosebleeds, was recorded with all drugs, but these
required no treatment or change of therapy. Skin bruising was
reported with all antiplatelet agents but it did not necessitate
change in therapy. No bradycardia was reported or recorded
with patients on ticagrelor.
5. Discussion
The results of this observational study, which evaluated the
percentage of platelet inhibition with ticagrelor, clopidogrel, or
prasugrel, as dual-antiplatelet therapy with aspirin in patients
who underwent PCI, demonstrated that ticagrelor therapy
was associated with a statistically signiﬁcant higher mean
percentage platelet inhibition (89.9%) as compared with
clopidogrel (67.4%) and prasugrel (85.2%). The study also
demonstrated ticagrelor sensitivity in 99.15% of the patients,
which was statistically signiﬁcantly higher than prasugrelsensitivity in 94.23% of the patients, and clopidogrel sensitivity
in 72.15% of the patients.
All current guidelines including the latest 2014 European
Society of Cardiology (ESC) and the European Association for
Cardio-Thoracic Surgery (EACTS) guidelines on myocardial
revascularization recommend P2Y12 inhibitors (clopidogrel,
ticagrelor, and prasugrel) as dual antiplatelet therapy along
with aspirin, in patients undergoing PCI.26
Although clopidogrel is recommended in these patients,
the irreversibility and disparity of platelet inhibition with
clopidogrel has led to dispute about its optimum dose and
timing of administration in patients undergoing PCI.26–29
Ticagrelor is observed to reach IPA of 80–90% approximately
in 2–4 h after a 180 mg loading dose,28,29 which is consistent
with the current study ﬁnding of a mean platelet inhibition of
89.9% in 24 h with 180 mg loading and 90 mg twice daily
maintenance dose of ticagrelor. Moreover, mean platelet
inhibition of 67.4% achieved with 300 mg loading and 75 mg
daily maintenance of clopidogrel within 24 h is comparable
with other studies, which reported a 30–50% platelet inhibition
with 300 mg and 600 mg loading dose of clopidogrel in
4–8 h.28,29
As discussed earlier, the PLATO trial demonstrated that
ticagrelor signiﬁcantly reduced the mortality rate due to
vascular events, myocardial infarction, and stroke, as com-
pared with clopidogrel, without an increase in the rate of major
bleeding.30 More interesting is the fact that a substudy of the
PLATO trial demonstrated that ticagrelor is associated with
increased and more reliable platelet inhibition than clopido-
grel,31 which is again consistent with the ﬁndings of this study.
Prasugrel is also an irreversible platelet inhibitor with the
pharmacological effects based on its conversion to an active
metabolite. However, unlike clopidogrel, the onset of action is
faster (<30 min with 60 mg loading dose).32 Despite its rapid
action, it is associated with increased risk of bleeding, as
demonstrated in the TRITON-TIMI 38 study.33 Prasugrel
resistance has not been described reliably and few studies
so far have reported resistance. Our study, probably one of the
few ones to do so, has demonstrated resistance to prasugrel in
5.77% of patients.
In 2012, Alexopoulos et al. reported that ticagrelor provided
stronger platelet inhibition than prasugrel using the Verify-
Now assay, attributing this to the nonhepatic mode of action of
ticagrelor. Although prasugrel is not inﬂuenced by CYP2C19
and CYP2C9 polymorphism, it may be inﬂuenced by other
abnormalities within the liver including other polymor-
phisms.34
5.1. Impact of clinical factors on the response to treatment
with ticagrelor, prasugrel, and clopidogrel
The current study also demonstrated that the antiplatelet
effect of ticagrelor was not inﬂuenced by any of the clinical
factors studied including age, weight, creatinine level, hyper-
tension, and diabetes. In fact, ticagrelor achieved statistically
signiﬁcantly higher mean platelet inhibition in all these
subgroups as compared with clopidogrel and prasugrel except
in patients with diabetes, where the difference between
ticagrelor and prasugrel was not signiﬁcant but the difference
between ticagrelor and clopidogrel was signiﬁcant.
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 6 2 4 – 6 3 1630A substudy of the PLATO trials demonstrated that in
patients with CKD, compared with clopidogrel, ticagrelor was
associated with a 23% reduction in the relative risk of the
primary ischemic endpoint (when compared with a nonsig-
niﬁcant 10% decrease in patients without CKD) and was
associated with even more striking reductions of 4.0% and 28%,
respectively, in the absolute and relative risks of all-cause
mortality.35 Also, Alexopoulos et al. reported prasugrel
resistance in 19% of patients with CKD and on hemodialysis.34
In this scenario, the ﬁndings from our study may have
signiﬁcant clinical implications towards the use of ticagrelor in
these subsets of patients.
As patients with diabetes mellitus (DM) have high platelet
reactivity and are at an increased risk of ischemic events, a
post hoc analysis of PLATO trial was conducted to study the
effect of ticagrelor vs. clopidogrel in patients with DM. The
study found that ticagrelor was associated with the reduction
in the primary composite endpoint (HR: 0.88, 95% CI: 0.76–
1.03), all-cause mortality (HR: 0.82, 95% CI: 0.66–1.01), and
stent thrombosis (HR: 0.65, 95% CI: 0.36–1.17), with no
increase in major bleeding (HR: 0.95, 95% CI: 0.81–1.12) in
patients with diabetes, as observed in the broad population of
patients with ACS in the PLATO trial.36 In another study,
Alexopoulos et al. directly compared the platelet inhibition
with ticagrelor vs. that with prasugrel in patients with DM
and ACS who had been pretreated with clopidogrel and
underwent PCI. They demonstrated that ticagrelor achieved
signiﬁcantly higher platelet inhibition than prasugrel in
these patients.37
Our study results indicate a similar beneﬁt in these
patients.
5.2. Efﬁcacy of ticagrelor in clopidogrel nonresponders
In our study, ticagrelor therapy overwhelmed nonresponsive-
ness to clopidogrel (14.87%) with the mean percent platelet
inhibition of 90% in these patients after switching over to
ticagrelor. Similar to our study, The Response to Ticagrelor in
Clopidogrel Nonresponders and Responders and Effect of
Switching Therapies (RESPOND) study, a substudy of the PLATO
trial, demonstrated that the IPA was higher in clopidogrel
nonresponders treated with ticagrelor compared with clopido-
grel ( p < 0.05). The IPA increased from 35  11% to 59  9% in
patients switched from clopidogrel to ticagrelor ( p < 0.0001) and
reduced from 56  9% to 36  14% in patients switched from
ticagrelor to clopidogrel ( p < 0.0001).38
5.3. Limitations of the study
While the results of this study are of signiﬁcant importance, it
has few limitations, the major one being its nonrandomised and
observational design. Moreover results may be considered as
indicative. However, we were able to capture a real life set of
patient population that is similar to that observed in other
studies of the same design. The baseline variables were similar
and any confounding variables are unlikely to have had any
effect on the results.
We also compared using only serum creatinine values,
whereas creatinine clearance would have provided better
information.Also only one test (TEG) was used to evaluate the mean
percentage platelet inhibition that was available in our
hospital 24/7. Platelet inhibition testing in vitro has its
limitations for predicting clinical events and TEG also suffers
from the same limitation, though some data of association
with clinical events have been published. We changed patients
resistant to prasugrel to ticagrelor because it was a newer
molecule that had just been introduced. We do not have any
information if clopidogrel had been used in these patients and
that decision remains with the treating physician. Finally, we
did not collect pharmacokinetic samples for the analysis of
clopidogrel or prasugrel metabolites or serum levels of
ticagrelor. Hence, it is beyond the scope of this study to
comment on the pharmacokinetic correlation with the
observed effects of the study drugs.
6. Conclusion
In patients with CAD undergoing PCI, the use of ticagrelor as
dual therapy along with aspirin was associated with a
signiﬁcantly higher mean percentage platelet inhibition,
higher sensitivity, and lower resistance, as compared with
clopidogrel and prasugrel. This was seen even in patients
resistant to either of the two drugs.
Conﬂicts of interest
The ﬁrst two authors have none to declare and the third author
is associated with Astra.
r e f e r e n c e s
1. Jha P, Gajalakshmi V, Gupta PC, et al. Prospective study of
one million deaths in India: rationale, design, and validation
results. PLoS Med. 2006;3:e18.
2. Gupta R, Guptha S, Sharma KK, et al. Regional variations in
cardiovascular risk factors in India: India heart watch. World
J Cardiol. 2012;4:112–120.
3. Kottke-Marchant K. Importance of platelets and platelet
response in acute coronary syndromes. Cleve Clin J Med.
2009;76(suppl 1):S2–S7.
4. Gachet C, Aleil B. Testing antiplatelet therapy. Eur Heart J
Suppl. 2008;10(suppl):A28–A34.
5. Thakur M, Ahmed AB. A review of thromboelastography.
IJPUT. 2012;1:25–29.
6. Wijeyeratne YD, Heptinstall S. Anti-platelet therapy: ADP
receptor antagonists. Br J Clin Pharmacol. 2011;72:647–657.
7. Wallentin L. P2Y12 inhibitors: differences in properties and
mechanisms of action and potential consequences for
clinical use. Eur Heart J. 2009;30:1964–1977.
8. Bonello L, Pansieri M, Mancini J, et al. High on-treatment
platelet reactivity after prasugrel loading dose and
cardiovascular events after percutaneous coronary
intervention in acute coronary syndromes. J Am Coll Cardiol.
2011;58:467–473.
9. Silvano M, Zambon CF, De Rosa G, et al. A case of resistance
to clopidogrel and prasugrel after percutaneous coronary
angioplasty. J Thromb Thrombolysis. 2011;31:233–234.
10. Morel O, Muller C, Jesel L, et al. Impaired platelet P2Y12
inhibition by thienopyridines in chronic kidney disease:
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 6 2 4 – 6 3 1 631mechanisms, clinical relevance and pharmacological
options. Nephrol Dial Transplant. 2013;28:1994–2002.
11. Nawarskas JJ, Snowden SS. Critical appraisal of ticagrelor in
the management of acute coronary syndrome. Ther Clin Risk
Manag. 2011;7:473–488.
12. Wiviott SD, Antman EM. Clopidogrel resistance: a new chapter
in a fast-moving story. Circulation. 2004;109:3064–3067.
13. Gasparyan AY. Aspirin and clopidogrel resistance:
methodological challenges and opportunities. Vasc Health
Risk Manag. 2010;6:109–112.
14. Guha S, Sardar P, Guha P, et al. Dual antiplatelet drug
resistance in patients with acute coronary syndrome. Indian
Heart J. 2009;61:68–73.
15. Jaremo P, Lindahl TL, Fransson SG, et al. Individual
variations of platelet inhibition after loading doses of
clopidogrel. J Intern Med. 2002;252:233–238.
16. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary
stenting: response variability, drug resistance, and the effect
of pretreatment platelet reactivity. Circulation.
2003;107:2908–2913.
17. Müller I, Besta F, Schulz C, et al. Prevalence of clopidogrel
non-responders among patients with stable angina pectoris
scheduled for elective coronary stent placement. Thromb
Haemost. 2003;89:783–787.
18. Mobley JE, Bresee SJ, Wortham DC, et al. Frequency of
nonresponse antiplatelet activity of clopidogrel during
pretreatment for cardiac catheterization. Am J Cardiol.
2004;93:456–458.
19. Lepantalo A, Virtanen KS, Heikkila J, et al. Limited early
antiplatelet effect of 300 mg clopidogrel in patients with
aspirin therapy undergoing percutaneous coronary
interventions. Eur Heart J. 2004;25:476–483.
20. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al.
Identiﬁcation of low responders to a 300-mg clopidogrel
loading dose in patients undergoing coronary stenting.
Thromb Res. 2005;115:101–108.
21. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel
resistance is associated with increased risk of recurrent
atherothrombotic events in patients with acute myocardial
infarction. Circulation. 2004;109:3171–3175.
22. Dziewierz A, Dudek D, Heba G, et al. Inter-individual
variability in response to clopidogrel in patients with
coronary artery disease. Kardiol Pol. 2005;62:108–117.
23. Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel
drug response in patients undergoing percutaneous
coronary intervention: the role of dual drug resistance. J Am
Coll Cardiol. 2006;47:27–33.
24. Kar R, Meena A, Yadav BK, et al. Clopidogrel resistance in
North Indian patients of coronary artery disease and lack of
its association with platelet ADP receptors P2Y1 and P2Y12
gene polymorphisms. Platelets. 2013;24:297–302.
25. Kumar S, Saran RK, Puri A, et al. Proﬁle and prevalence of
clopidogrel resistance in patients of acute coronary
syndrome. Indian Heart J. 2007;59:152–156.26. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS
Guidelines on myocardial revascularization. The Task Force on
Myocardial Revascularization of the European Society of
Cardiology (ESC) and the European Association for Cardio-
Thoracic Surgery (EACTS). http://eurheartj.oxfordjournals.org/
content/ehj/early/2014/09/10/eurheartj.ehu278.full.pdf.
Accessed 30.12.14.
27. Plavix® (clopidogrel bisulfate) tablets [prescribing information]
Bridgewater, NJ. Sanoﬁ Aventis. http://www.accessdata.fda.
gov/drugsatfda_docs/label/2013/020839s058lbl.pdf.
28. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-
blind assessment of the ONSET and OFFSET of the
antiplatelet effects of ticagrelor versus clopidogrel in
patients with stable coronary artery disease: the ONSET/
OFFSET study. Circulation. 2009;120:2577–2585.
29. Storey RF, Husted S, Harrington RA, et al. Inhibition of
platelet aggregation by AZD6140, a reversible oral P2Y12
receptor antagonist, compared with clopidogrel in patients
with acute coronary syndromes. J Am Coll Cardiol.
2007;50:1852–1856.
30. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus
clopidogrel in patients with acute coronary syndromes. N
Engl J Med. 2009;361:1045–1057.
31. Storey RF, Angiolillo DJ, Patil SB, et al. Inhibitory effects of
ticagrelor compared with clopidogrel on platelet function in
patients with acute coronary syndromes. J Am Coll Cardiol.
2010;56:1456–1462.
32. Efﬁent® (prasugrel) tablets [prescribing information] Indianapolis,
IN. Eli Lilly and Company. http://www.accessdata.fda.gov/
drugsatfda_docs/label/2009/022307s000lbl.pdf.
33. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus
clopidogrel in patients with acute coronary syndromes. N
Engl J Med. 2007;357:2001–2015.
34. Alexopoulos D, Panagiotou A, Xanthopoulou I, et al.
Antiplatelet effects of prasugrel vs. double clopidogrel in
patients on hemodialysis and with high on-treatment
platelet reactivity. J Thromb Haemost. 2011;9:2379–2385.
35. James S, Budaj A, Aylward P, et al. Ticagrelor versus
clopidogrel in acute coronary syndromes in relation to renal
function: results from the Platelet Inhibition and Patient
Outcomes (PLATO) trial. Circulation. 2010;122:1056–1067.
36. James S, Angiolillo DJ, Cornel JH, et al. Ticagrelor vs.
clopidogrel in patients with acute coronary syndromes
and diabetes: a substudy from the PLATelet inhibition
and patient Outcomes (PLATO) trial. Eur Heart J. 2010;31:
3006–3016.
37. Alexopoulos D, Xanthopoulou I, Mavronasiou E, et al.
Randomized assessment of ticagrelor versus prasugrel
antiplatelet effects in patients with diabetes. Diabetes Care.
2013;36:2211–2216.
38. Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in
clopidogrel nonresponders and responders and effect of
switching therapies: the RESPOND study. Circulation.
2010;121:1188–1199.
